Immunotherapies for Immune-Mediated myopathies: A current perspective
Tools
Tools
Needham, M. and Mastaglia, F.L. (2015) Immunotherapies for Immune-Mediated myopathies: A current perspective. Neurotherapeutics, 13 (1). pp. 132-146.
*Subscription may be required
*No subscription required
Abstract
Until recently, the treatment of immune-mediated inflammatory myopathies has largely been empirical with glucocorticoids, steroid-sparing immunosuppressive drugs, and intravenous immunoglobulin. However, a proportion of patients are only partially responsive to these therapies, and there has been a need to consider alternative treatment approaches. In particular, patients with inclusion body myositis are resistant to conventional immunotherapies or show only a transient response, and remain a major challenge. With increasing recognition of the different subtypes of immune-mediated inflammatory myopathies, and improved understanding of their pathogenesis, more targeted treatments are now being trialled. The overall approach to treatment, and novel therapies targeting B cells, T cells, and specific cytokines are discussed in this review.
| Item Type: | Journal Article |
|---|---|
| Murdoch Affiliation(s): | Institute for Immunology and Infectious Diseases |
| Publisher: | Springer US |
| URI: | http://researchrepository.murdoch.edu.au/id/eprint/29152 |
 |
Item Control Page |